Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Long-Term Investments (2014 - 2017)

AC Immune (ACIU) reported Long-Term Investments of $127711.0 for Q4 2017, up 48.5% year-over-year from $86002.1 in Q4 2016, and up 1.77% on a QoQ basis from $125491.4 in Q1 2017.

AC Immune (ACIU) has 4 years of Long-Term Investments data on file, last reported at $127711.0 in Q4 2017.

  • Quarterly Long-Term Investments rose 48.5% year-over-year to $127711.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $127711.0 (up 48.5% YoY) and the FY2017 annual result came in at $127711.0, up 48.5% from the prior year.
  • Long-Term Investments advanced to $127711.0 in Q4 2017 per ACIU's latest filing, from $125491.4 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $127711.0 in Q4 2017 and bottomed at $85895.2 in Q4 2015.
  • The 4-year median for Long-Term Investments is $87665.5 (2014), against an average of $100071.8.
  • The widest annual swing landed in 2015, when Long-Term Investments dropped 2.61%; it then surged 48.5% in 2017.
  • Tracing ACIU's Long-Term Investments over 4 years: stood at $88195.7 in 2014, then decreased by 2.61% to $85895.2 in 2015, then climbed by 0.12% to $86002.1 in 2016, then surged by 48.5% to $127711.0 in 2017.
  • Per Business Quant, the three latest ACIU Long-Term Investments figures stand at $127711.0 (Q4 2017), $125491.4 (Q1 2017), and $86002.1 (Q4 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 505,194.89
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 9.79 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 22.17 Mn
10 AC Immune 325.88 Mn 211.53 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 127,710.99
Mar 31, 2017 125,491.40
Dec 31, 2016 86,002.10
Sep 30, 2016 87,135.25
Dec 31, 2015 85,895.22
Dec 31, 2014 88,195.70